Another Big Win for Big Biotech Biogen?
Biogen , one of the best performing big biotechs of 2013, reported solid third-quarter results today and hovered around an all-time high, but shares were up less than 1% when the market closed. In the following video, from The Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss the updated results from the launch of Biogen's newest multiple sclerosis drug, Tecfidera, and reasons why the company's hemophilia A drug Eloctate put a damper on today's results.
An amazing growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article Another Big Win for Big Biotech Biogen? originally appeared on Fool.com.Alison Southwick owns shares of Apple. David Williamson owns shares of Facebook. Max Macaluso, Ph.D., owns shares of Apple and Facebook. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.